Executive Summary Mounjaro, a diabetes and weight-loss injection that reached India only in 2025, is now the country’s best-selling brand, with ₹923 crore in sales in the 12 months to Marc...
Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
Key Highlights: Implications: Novartis India’s acquisition of the Minipress and Minipres trademarks from Pfizer gives it an established cardiovascular brand in hypertension and B...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
